SBIR/STTR Research Award

TILLING Wheat for Reduced Celiac Disease Causing Proteins

Award identifier 5eb79b6120c7c19d7a7bb98275a0acc1eb6a6506d0d775bf3fe8dc12ffb0c4b5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

STTR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Anawah, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Celiac disease is an autoimmune digestive disorder in which intestinal lesions develop in genetically susceptible individuals in response to the ingestion of specific seed storage proteins found in cereal grains. The only treatment is strict adherence to a diet from which the offending grains have been eliminated. Therefore, considerable research has been devoted to identifying the specific amino acid sequences in wheat seed storage proteins responsible for eliciting the immune reaction in celiac patients, and this research has motivated the hope that strains of wheat and other grains could be developed in which these proteins have been reduced or eliminated. Anawah has successfully developed a novel, non GMO (genetically modified organism) target-selected mutation breeding approach called TILLING (Targeting Induced Local Lesions in Genomes). In collaboration with Dr. Diter von Wettstein of Washington State University, we will apply TILLING to develop lines of wheat in which some of the gliadins, which are believed to be the most potent antigens responsible for celiac disease, have been modified or eliminated. This NIH STTR Phase I proposal will result in novel lines of wheat that will serve both as research tools to genetically define the most potent elicitors of the lesions found in celiac disease patients as well as sources of novel germplasm that will form the basis of Phase II research and development aimed at producing varieties of wheat that lack prominent disease causing autoimmunogenic epitopes in the gluten. The objective of our Phase I STTR propsal will be met with the following specific aims: 1. Design PCR primers, based upon the available wheat gliadin DNA sequences, to specifically amplify, from genomic DNA of tetraploid pasta wheat, subsets of the gliadins that are believed to be the most toxic to celiac disease patients. 2. Use these primers to identify null and missense alleles of these genes in our wheat TILLING library of genetic variants. 3. Prioritize plants containing new alleles of the targeted gliadins for marker-assisted crossing. 4. Using a variety of methods including 2D PAGE of seed endosperm proteins, we will begin phenotypic characterization of the progeny of the plants containing the high priority induced alleles that we identify.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.